| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| License and other revenue | 0 | 0 | 15,000 | - |
| Research and development | 41,563 | 42,741 | 33,443 | 33,903 |
| General and administrative | 12,227 | 11,912 | 12,334 | 12,502 |
| Loss from operations | -53,790 | -54,653 | -30,777 | -46,405 |
| Interest and investment income | 3,765 | 4,380 | 7,890 | 3,340 |
| Interest expense | 2,890 | 2,884 | 2,877 | 2,557 |
| Other non-operating income (expense), net | -1,810 | 3,592 | 1,026 | 3,664 |
| Loss before income taxes | -54,725 | -49,565 | -24,738 | -41,958 |
| Income tax expense | 166 | 778 | 1,397 | 608 |
| Net loss | -54,891 | -50,343 | -26,135 | -42,566 |
| Foreign currency translation adjustment | 691 | -479 | 643 | -412 |
| Unrealized gain on available for sale marketable securities, net of tax | - | - | - | 912 |
| Unrealized (loss) gain on available for sale marketable securities, net of reclassification adjustment and tax | 318 | -5 | -2,781 | - |
| Other comprehensive (loss) income | 1,009 | -484 | -2,138 | 500 |
| Total comprehensive loss | -53,882 | -50,827 | -28,273 | -42,066 |
| Net loss per ordinary share - basic (in dollars per share) | -0.41 | -0.38 | -0.2 | -0.37 |
| Net loss per ordinary share - diluted (in dollars per share) | -0.41 | -0.38 | -0.2 | -0.37 |
| Weighted average ordinary shares outstanding - basic (in shares) | 134,163,492 | 133,677,405 | 133,033,541 | 116,253,902 |
| Weighted average ordinary shares outstanding - diluted (in shares) | 134,163,492 | 133,677,405 | 133,033,541 | 116,253,902 |
Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc (CNTA)